Should central serous chorioretinopathy be added to the list of ocular side effects of phosphodiesterase 5 inhibitors?

Ophthalmologica

Volumn 227, Issue 2, 2012, Pages 85-89

  Aliferis, K ^a   Petropoulos, I K ^b   Farpour, B ^a   Matter, M A ^b   Safran, A B ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b Ophthalmological Center of Rive   (Switzerland)

Author keywords

Central serous chorioretinopathy; Phosphodiesterase 5 inhibitors; Tadalafil; Vardenafil

Indexed keywords

PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; TADALAFIL; VARDENAFIL;

ADULT; AGED; BLURRED VISION; CASE REPORT; CENTRAL SEROUS RETINOPATHY; DRUG WITHDRAWAL; FLUORESCENCE ANGIOGRAPHY; HUMAN; MALE; MICROPSIA; OPHTHALMOSCOPY; OPTICAL COHERENCE TOMOGRAPHY; REVIEW; VISUAL ACUITY; VISUAL DISORDER;

AGED; CARBOLINES; CENTRAL SEROUS CHORIORETINOPATHY; ERECTILE DYSFUNCTION; FLUORESCEIN ANGIOGRAPHY; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; SULFONES; TOMOGRAPHY, OPTICAL COHERENCE; TRIAZINES; VISION DISORDERS;

EID: 84856425896     PISSN: 00303755     EISSN: 14230267     Source Type: Journal    
DOI: 10.1159/000333824     Document Type: Review

References (24)

1. Yannuzi LA: Type-A behavior and central serous chorioretinopathy. Retina 1987;7:111-131.
2. Kitzmann AS, Pulido JS, Diehl NN, Hodge DO, Burke JP: The incidence of central serous chorioretinopathy in Olmsted Country, Minnesota, 1980-2002. Ophthalmology 2008;115:169-173.
3. Wang M, Munch IC, Hasler PW, Prünte C, Larsen M: Central serous chorioretinopathy. Acta Ophthalmol 2008;86:126-145.
4. Regillo C, Chang TS, Johnson MW, Kaiser PK, Scott IU, Spaide R, Griggs PB: Retina and Vitreous. Section 12. Basic and Clinical Science Course. San Francisco, American Academy of Ophthalmology, 2007, pp 51-54.
5. Kanski JJ: Clinical Ophthalmology. A Systematic Approach, ed 5. Oxford, Butterworth-Heinemann, 2003, pp 421-423.
6. Gass J-graveM: Stereoscopic Atlas of Macular Diseases, ed 4. St Louis, Mosby, 1997, pp 52-70.
7. Tittl MK, Spaide RF, Wong D, Pilotto E, Yanuzzi LA, Fisher YL, Freund B, Guyer DR, Slakter JS, Sorenson JA: Systemic findings associated with central serous chorioretinopathy. Am J Ophthalmol 1999;128:63-68.
8. Bouzas EA, Karadimas P, Pournaras CJ: Central serous chorioretinopathy and glucocorticoids. Surv Ophthalmol 2002;47:431-448.
9. Quillen DA, Gass DM, Brod R-grave, Gardner TW, Blankenship GW, Gottlieb JL: Central serous chorioretinopathy in women. Ophthalmology 1996;103:72-9.
10. Murata M, Ideta H, Kawasaki T, Noda Y: A case of central serous chorioretinopathy after sildenafil (Viagra) administration. Kyushu Ganka Gakkai 2000;42:727-730.
11. Allibhai ZA, Gale JS, Sheidow TS: Central serous chorioretinopathy in a patient taking sildenafil citrate. Ophthalmic Surg Lasers Imaging 2004;35:165-167.
12. Quiram P, Dumars W, Parwar P, Sarraf D: Viagra-associated serous macular detachment. Graefes Arch Clin Exp Ophthalmol 2005;243:339-344.
13. Fraunfelder FW, Fraunfelder FT: Central serous chorioretinopathy associated with sildenafil. Retina 2008;28:606-609.
14. Nadeau S, Nguyen F, Guigou S: Serous central chorioretinopathy and tadalafil: a case report. J Fr Ophthalmol 2011, E-pub ahead of print.
15. ®. Full prescribing information for sildenafil citrate. Zurich, Pfizer, 2009.
16. ®. Full prescribing information for tadalafil. Geneva, Lilly, 2009.
17. ®. Full prescribing information for vardenafil. Zurich, Bayer, 2009.
18. Fraunfelder FW, Pomeranz H-grave, Egan RA: Nonarteritic anterior ischemic optic neuropathy and sildenafil. Arch Ophthalmol 2006;124:733-734.
19. Laties AM: Vision disorders and phosphodiesterase type 5 inhibitors. A review of the evidence to date. Drug Safety 2009;32:1-18.
20. French D-grave, Margo CE: Central serous chorioretinopathy and phosphodiesterase-5 inhibitors. A case-control postmarketing surveillance study. Retina 2010;30:271-274.
21. McCulley TJ, Luu JK, Marmor MF, Feuer WJ: Effects of sildenafil citrate (Viagra) on choroidal congestion. Ophthalmologica 2002;216:455-458.
22. Foresta C, Caretta N, Zuccarello D, Poletti A, Biagioli A, Caretti L, Galan A: Expression of the P-graveE5 enzyme on human retinal tissue: new aspects of P-graveE5 inhibitors ocular side effects. Eye 2008;22:144-149.
23. Marmor MF, Kessler R: Sildenafil (Viagra) and ophthalmology. Surv Ophthalmol 1999;44:153-162.
24. Laties AM, Zrenner E: Viagra (sildenafil citrate) and ophthalmology. Prog Retin Eye Res 2002;21:485-506.